COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.

Melanoma & Skin

  • EA6134 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
  • EA6191 The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double-Blind Phase II study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K melanoma with elevated LDH2
  • S1801 A Phase II Randomized Study of Adjuvant Vs. Neoadjuvant MK-3475 (Pembrolizumab) for clinically Detectable Stage III-IV High Risk Melanoma
  • S2000 A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF V6000 Mutant Melanoma with brain Metastases
  • A091802   Phase II Randomized trial of Avelumab Plus Cetuximab versus Avelumab alone in advanced cutaneous squamous cell carcinoma of the skin
  • EA6174  STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III trial